Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers. Aadi Bioscience serves patients in the United States.

Current Report (Form 8-K | Period ending 2025-03-18)

DEFM14A | Definitive proxy statement relating to merger or acquisition

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Aadi Bioscience (AADI US)

Current Report (Form 8-K | Period ending 2025-03-18)

DEFM14A | Definitive proxy statement relating to merger or acquisition

Current Report (Form 8-K | Period ending 2024-12-19)

Quarterly Report (Form 10-Q | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-06)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)